Pharmacokinetics and safety of ticagrelor in infants and toddlers with sickle cell disease aged <24 months

Pharmacokinetics and safety of ticagrelor in infants and toddlers with sickle cell disease aged <24 months

Inhibition of platelet activation may reduce vaso‐occlusion rates in patients with sickle cell disease (SCD). In the HESTIA4 (NCT03492931) study, 21 children with SCD received a single oral dose of the antiplatelet agent ticagrelor (0.1 mg/kg

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pediatric blood & cancer 2021-05, Vol.68 (5), p.e28977-n/a
Hauptverfasser: Duniva Inusa, Baba Psalm, Inati, Adlette, Maes, Philip, Githanga, Jessie, Ogutu, Bernhards, Abboud, Miguel R., Miano, Maurizio, Cela, Elena, Nduba, Videlis, Niazi, Mohammad, Åstrand, Magnus, Persson, Kevin, Berggren, Anders, Carlson, Glenn
Format: Artikel
Sprache:eng
Schlagworte:
Children
Hematology
Infants
Occlusion
Oncology
paediatric
Palatability
Pediatrics
pharmacokinetic
Pharmacokinetics
Sickle cell disease
ticagrelor
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Inhibition of platelet activation may reduce vaso‐occlusion rates in patients with sickle cell disease (SCD). In the HESTIA4 (NCT03492931) study, 21 children with SCD received a single oral dose of the antiplatelet agent ticagrelor (0.1 mg/kg
ISSN:1545-5009
1545-5017
DOI:10.1002/pbc.28977